Edition:
India

CareDx Inc (CDNA.OQ)

CDNA.OQ on NASDAQ Stock Exchange Global Market

26.04USD
1:30am IST
Change (% chg)

$-2.37 (-8.34%)
Prev Close
$28.41
Open
$28.26
Day's High
$28.26
Day's Low
$25.60
Volume
227,518
Avg. Vol
284,246
52-wk High
$41.27
52-wk Low
$19.14

Latest Key Developments (Source: Significant Developments)

CareDx Files Patent Infringement Lawsuit Against Eurofins Viracor
Thursday, 26 Sep 2019 

Sept 26 (Reuters) - CareDx Inc ::CAREDX FILES PATENT INFRINGEMENT LAWSUIT AGAINST EUROFINS VIRACOR.CAREDX INC - ASSERTING A U.S. PATENT WHICH IS EXCLUSIVELY LICENSED TO CO FROM STANFORD UNIVERSITY.CAREDX INC - SEEKING ALL AVAILABLE REMEDIES IN PATENT INFRINGEMENT LAWSUIT AGAINST EUROFINS VIRACOR.  Full Article

CareDx Reports Q2 Loss Per Share $0.19
Friday, 2 Aug 2019 

Aug 1 (Reuters) - CareDx Inc ::CAREDX REPORTS SECOND QUARTER 2019 RESULTS.Q2 NON-GAAP EARNINGS PER SHARE $0.00.Q2 LOSS PER SHARE $0.19.Q2 REVENUE $31.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $28 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $0.00 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $123 MILLION TO $125 MILLION.  Full Article

Caredx Inc Says Has Filed A Second Lawsuit Against Natera, Inc.
Wednesday, 10 Apr 2019 

April 10 (Reuters) - CareDx Inc ::CAREDX INC - HAS FILED A SECOND LAWSUIT AGAINST NATERA, INC..CAREDX- ALLEGES NATERA'S COMPARISONS OF KIDNEY TRANSPLANT TECH TO CO'S ALLOSURE TECH ARE BASED ON "INAPPROPRIATE CONCLUSIONS".CAREDX INC - CAREDX IS SEEKING ALL AVAILABLE REMEDIES, INCLUDING MONETARY DAMAGES.  Full Article

CareDx Files Patent Infringement Lawsuit Against Natera
Tuesday, 26 Mar 2019 

March 26 (Reuters) - CareDx Inc ::CAREDX FILES PATENT INFRINGEMENT LAWSUIT AGAINST NATERA.CAREDX - SUIT ASSERTS NATERA INFRINGES THROUGH MARKETING & PERFORMANCE OF TEST TO ANALYZE CELL-FREE DNA FROM TRANSPLANT PATIENT TO INFORM REJECTION.  Full Article

Caredx announces full repayment of its outstanding debt
Monday, 26 Nov 2018 

Nov 26 (Reuters) - CareDx Inc ::CAREDX ANNOUNCES FULL REPAYMENT OF ITS OUTSTANDING DEBT.CAREDX INC - PREPAID IN FULL ITS OUTSTANDING DEBT ON NOVEMBER 20, 2018..CAREDX INC - PREPAID DEBT, A $15 MILLION TERM LOAN FROM PERCEPTIVE ADVISORS, WAS OBTAINED ON APRIL 13, 2018.CAREDX INC - IN ADDITION TO $15 MILLION DEBT PREPAYMENT, COMPANY ALSO PAID PERCEPTIVE ADVISORS A PREPAYMENT PREMIUM AND AN EXIT FEE.  Full Article

CareDx Prices Public Offering Of 2 Mln Common Shares At $24.5/Shr
Wednesday, 14 Nov 2018 

Nov 13 (Reuters) - CareDx Inc ::CAREDX ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 2.00 MILLION COMMON SHARES PRICED AT $24.50PER SHARE.  Full Article

CareDx Announces Proposed Public Offering Of Common Stock
Wednesday, 14 Nov 2018 

Nov 13 (Reuters) - CareDx Inc ::CAREDX ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CAREDX INC - INTENDS TO OFFER AND SELL 2 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Caredx Inc Files For Mixed Shelf Offering Of Up To $200 Million
Saturday, 1 Sep 2018 

Aug 31 (Reuters) - CareDx Inc ::CAREDX INC FILES FOR MIXED SHELF OFFERING OF UP TO $200 MILLION.  Full Article

Olerup QTYPE Receives CE Mark Certification
Friday, 13 Apr 2018 

April 13 (Reuters) - Caredx Inc ::OLERUP QTYPE® RECEIVES CE MARK CERTIFICATION.OLERUP QTYPE RECEIVED CE MARK APPROVAL AND IS AVAILABLE ON BOTH ROCHE & APPLIED BIOSYSTEMS PLATFORMS.  Full Article

Caredx Launches Heartcare For Heart Transplant Recipients
Tuesday, 10 Apr 2018 

April 10 (Reuters) - CareDx Inc ::CAREDX LAUNCHES HEARTCARE® FOR HEART TRANSPLANT RECIPIENTS.ANNOUNCED LAUNCH OF HEARTCARE, A COMPREHENSIVE REJECTION SURVEILLANCE SOLUTION FOR HEART TRANSPLANT RECIPIENTS.  Full Article